ARYx Therapeutics, Inc. (ARYX)

ARYx Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005
Period Ending	Sep 30, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005
Revenue	-	-	19.72	4.16	4.74	-
Revenue Growth (YoY)	-	-	374.36%	-12.26%	-	-
Cost of Revenue	-	-	0.23	0.26	2.12	-
Gross Profit	-	-	19.49	3.9	2.62	-
Selling, General & Admin	8.07	10.2	10.07	7.7	6.94	5.67
Research & Development	7.06	21.04	39.84	24.99	23.97	22.5
Operating Expenses	15.13	31.24	49.91	32.7	30.91	28.17
Operating Income	-15.13	-31.24	-30.42	-28.8	-28.29	-28.17
Interest Expense	-1.69	-2.01	-1.93	-1.35	-1.32	-0.67
Interest & Investment Income	0.07	0.09	1.26	2.59	2.29	0.88
EBT Excluding Unusual Items	-16.75	-33.15	-31.09	-27.56	-27.32	-27.96
Gain (Loss) on Sale of Investments	0.02	-0.01	-0.13	-	-	-
Pretax Income	-18.33	-33.17	-31.22	-27.56	-27.32	-27.96
Earnings From Continuing Operations	-18.33	-33.17	-31.22	-27.56	-27.32	-27.96
Net Income	-18.33	-33.17	-31.22	-27.56	-27.33	-27.96
Net Income to Common	-18.33	-33.17	-31.22	-27.56	-27.33	-27.96
Shares Outstanding (Basic)	31	27	19	3	1	1
Shares Outstanding (Diluted)	31	27	19	3	1	1
Shares Change (YoY)	17.87%	44.69%	466.77%	228.68%	11.87%	6.06%
EPS (Basic)	-0.59	-1.21	-1.65	-8.24	-26.84	-30.73
EPS (Diluted)	-0.59	-1.21	-1.65	-8.24	-26.84	-30.73
Free Cash Flow	-20.12	-35.11	-45.86	-28.2	-5.18	-26.28
Free Cash Flow Per Share	-0.65	-1.28	-2.42	-8.43	-5.08	-28.88
Gross Margin	-	-	98.82%	93.70%	55.35%	-
Operating Margin	-	-	-154.21%	-692.64%	-596.92%	-
Profit Margin	-	-	-158.27%	-662.84%	-576.66%	-
Free Cash Flow Margin	-	-	-232.52%	-678.31%	-109.20%	-
EBITDA	-14.18	-30.16	-29.32	-27.79	-27.46	-27.61
EBITDA Margin	-	-	-148.65%	-	-	-
D&A For EBITDA	0.95	1.08	1.1	1.01	0.83	0.56
EBIT	-15.13	-31.24	-30.42	-28.8	-28.29	-28.17
EBIT Margin	-	-	-154.21%	-	-	-
Revenue as Reported	-	-	19.72	4.16	4.74	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.